Kyverna Therapeutics (KYTX) executive compensation, 2026 proxy

Warner Biddle, Chief Executive Officer, was paid $1.8M in 2025, down 88% from $15M the year before.

Filed
April 13, 2026
Annual meeting
May 27, 2026
Pay year
2025
Named executives
3
CEO total pay
$1.8M-88% vs prior year
CEO Base Salary
$625,000Annual base salary
CEO Target Bonus
60%Percentage of base salary
CEO Option Awards
$543,804Grant date fair value

How Biddle was paid

$1.8M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary34%Option awards30%Non-equity incentive26%All other compensation10%

Named executive officers

ExecutiveTotal
Warner BiddleChief Executive Officer$1,814,980
Marc Grasso, M.D.Chief Financial Officer$1,663,536
Naji Gehchan, M.D.Chief Medical and Development Officer$2,085,173

What changed and why

  • $1.8MCEO Warner Biddle received total compensation of $1,814,980 for fiscal 2025 compared to $14,992,897 in 2024.
  • $625KBase salary was established at $625,000 for the CEO and $510,000 for other NEOs.
  • $469KAnnual non-equity incentives of $468,750 were awarded to the CEO based on performance.
  • $172KRelocation and moving expenses of $172,426 were provided to the CEO during 2025.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.